RxDoctor Payments Data

Gregory Cook, MD

Internal Medicine · Richmond, VANPI 1114135092

Payments from drug & device makers

$1,949in general payments, 2019–2025

Across 118 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$387
  • AstraZeneca$213
  • Lilly USA, LLC$178
  • Amgen$167
  • Sanofi-aventis U.S. LLC$157
  • Merck$130
  • plus $717 from 16 others

What the payments were for

  • Food & beverage$1,93499%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,949 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$183,928
Medicare patients
224
Services billed
1,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$55,148
OzempicSemaglutide27$30,817
JardianceEmpagliflozin49$30,374
MyrbetriqMirabegron51$25,818
TrulicityDulaglutide30$18,847
BriviactBrivaracetam36$16,412
XareltoRivaroxaban26$15,174
MounjaroTirzepatide14$14,727
Escitalopram Oxalate330$6,919
OxycontinOxycodone Hcl33$5,949
Rosuvastatin Calcium179$4,609
Atorvastatin Calcium218$3,817
JanuviaSitagliptin Phosphate12$3,552
Memantine Hcl57$3,129
PaxlovidNirmatrelvir/Ritonavir19$3,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$28$58,206119 claims
Lilly USA, LLCTrulicity, Mounjaro$178$33,57444 claims
Novo NordiskOzempic$387$30,81727 claims
Boehringer IngelheimJardiance$13$30,37449 claims
Johnson & JohnsonXarelto$37$15,17426 claims
MerckJanuvia$130$3,55212 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$26$2,862276 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →